January 9-12, 2023 – Are You Attending?

J.P. Morgan (JPM) 2023 41st Annual Healthcare Conference in San Francisco

Optimize your sell-side deal-making at JPM. Let Vault’s executive team help you develop and build-out your JPM walk-around deck.
Get Started

January 9-12, 2023 – Are You Attending?

J.P. Morgan (JPM) 2023 41st Annual Healthcare Conference in San Francisco

Optimize your sell-side deal-making at JPM. Let Vault’s executive team help you develop and build-out your JPM walk-around deck.
Get Started
Why Partner with Vault?

Sell-side or buy-side, we know what is important and how to express it.

Sell-Side Business Impact Study

Mid-size Pharma

Situation

A client had two CRL letters to show for two submissions of their metabolic disease asset. The issues involved phase 3 safety & efficacy data critical for approval and subsequent licensing. As product was to be discussed at FDA’s EMDAC prior to approval, Vault Bio was hired to conduct full diligence on NDA submission quality and ability to be approved.

Approach

  • Evaluated entire data package and recommended shift in strategy to enhance benefit/risk profile.
  • Implemented strategy and assisted in developing the EMDAC Briefing Document and helping guide FDA meeting prep.

Impact

EMDAC strongly voted to recommend product approval in T1D (13-1) and in T2D (14-0) based on Briefing Document and meeting data presentation, ultimately enabling a commercial licensing deal.

Buy-Side Business Impact Study

Top 10 Pharma

Situation

CEO hired Vault to provide diligence on an asset in light of a potential acquisition. Vault conducted commercial value diligence to identify key risks and upside opportunity.

Approach

  • Vault performed rapid asset analysis based on differentiating drug attributes and competitive considerations. Several critical risks and potential upsides were identified.
  • Vault built an analytical case to compress the downside and shift significant potential value from the seller to the buyer.
  • Partnered with the internal BD leads to develop negotiation and deal-terms highly favorable to the client.

Impact

Based on the deal, the client was a finalist for ‘Licensing Deal of the Year’ for the innovative deal structure. The product was licensed, launched, and performed to the downside case per the identified risk. Because of the risk mitigation and deal-structure, the losses were negligible.

Our Leadership Team has Walked in Your Shoes

We have helped small pharma, biotech, medical device and digital therapeutics startups through global enterprises design and develop highly differentiated products, build and sustain better brands, and forge stronger businesses.

Why Partner with Vault?

Sell-side or buy-side, Vault knows what is needed for a deal and how to express it.

Sell-Side Business Impact Study

Mid-size Pharma

Situation

A client had two CRL letters to show for two submissions of their metabolic disease asset. The issues involved phase 3 safety & efficacy data critical for approval and subsequent licensing. As product was to be discussed at FDA’s EMDAC prior to approval, Vault Bio was hired to conduct full diligence on NDA submission quality and ability to be approved.

Approach

  • Evaluated entire data package and recommended shift in strategy to enhance benefit/risk profile.
  • Implemented strategy and assisted in developing the EMDAC Briefing Document and helping guide FDA meeting prep.

Impact

EMDAC strongly voted to recommend product approval in T1D (13-1) and in T2D (14-0) based on Briefing Document and meeting data presentation, ultimately enabling a commercial licensing deal.

Buy-Side Business Impact Study

Top 10 Pharma

Situation

CEO hired Vault to provide diligence on an asset in light of a potential acquisition. Vault conducted commercial value diligence to identify key risks and upside opportunity.

Approach

  • Vault performed rapid asset analysis based on differentiating drug attributes and competitive considerations. Several critical risks and potential upsides were identified.
  • Vault built an analytical case to compress the downside and shift significant potential value from the seller to the buyer.
  • Partnered with the internal BD leads to develop negotiation and deal-terms highly favorable to the client.

Impact

Based on the deal, the client was a finalist for ‘Licensing Deal of the Year’ for the innovative deal structure. The product was licensed, launched, and performed to the downside case per the identified risk. Because of the risk mitigation and deal-structure, the losses were negligible.

Our Leadership Team has Walked in Your Shoes

We have helped small pharma, biotech, medical device and digital therapeutics startups through global enterprises design and develop highly differentiated products, build and sustain better brands, and forge stronger businesses.

Our Leadership Team has Walked in Your Shoes

We have helped small pharma, biotech, medical device and digital therapeutics startups through global enterprises design and develop highly differentiated products, build and sustain better brands, and forge stronger businesses.

We Can Help You Prepare for JPM 2023

  • Financial modeling/value quantification
  • Building a short but effective story around your company and/or asset
  • We execute highly effective presentations of the story and the value
Get Started

Don’t Go It Alone.

Vault Bioventures can help you express the value of your asset/company – CLEARLY. QUICKLY. EFFECTIVELY.

Vault Overview Deck
Vault Deck

Powerful Ideas Powerfully Communicated

Vault’s ability to analyze the science and bridge to the business strategically, verbally, and visually communicates the true, and often hidden value of your life science products, brands, and businesses.

Financial Modeling &
Value Quantification

  • Forecasting
  • eNPV
  • Competitive analysis
  • Value expression

Story Telling, Evolution,
Messaging & Narrative

  • Differentiation
  • Market opportunity
  • Competitive considerations
  • The value

Highly Effective Presentation
of The Story & Value

  • Not just words on slides
  • We craft data driven presentations that align with investor needs
  • We design, develop, and evolve your content and visual assets

Powerful Ideas Powerfully Communicated

Vault’s ability to analyze the science and bridge to the business strategically, verbally, and visually communicates the true, and often hidden value of your life science products, brands, and businesses.

Financial Modeling &
Value Quantification

  • Forecasting
  • eNPV
  • Competitive analysis
  • Value expression

Story Telling, Evolution,
Messaging & Narrative

  • Differentiation
  • Market opportunity
  • Competitive considerations
  • The value

Effective Presentation of The Story & Value

  • Not just words on slides
  • We craft data driven presentations that align with investor needs
  • We design, develop, and evolve your content and visual assets
Meet CEO Joe Young & SVP Joachim Osther

Vault Leadership for J.P. Morgan (JPM) 2023 41st Annual Healthcare Conference

Meet CEO Joe Young & SVP Joachim Osther

Vault Leadership for J.P. Morgan (JPM) 2023 41st Annual Healthcare Conference

Let Vault Help You Tell Your Story

Partnering with you to transform patients’ lives by uncovering and communicating the true,
and often hidden value of your life science products, brands, and businesses.

Get Started

Let Vault Help You Tell Your Story

Partnering with you to transform patients’ lives by uncovering and communicating the true,
and often hidden value of your life science products, brands, and businesses.

Get Started